• Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

ReNeuron Group PLC

+ Add to Watchlist


3.395 GBp 0.025 0.73%

As of 11:35:16 ET on 07/11/2014.

Snapshot for ReNeuron Group PLC (RENE)

Open: 3.300 Day's Range: 3.300 - 3.395 Volume: 412,963
Previous Close: 3.420 52wk Range: 2.610 - 4.300 1-Yr Rtn: +25.74%

Stock Chart for RENE

No chart data available.
  • RENE:LN 3.395
  • 1D
  • 1M
  • 1Y
Interactive RENE Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RENE

Current P/E Ratio (ttm) -
Estimated P/E(03/2015) -
Relative P/E vs. UKX -
Earnings Per Share (GBP) (ttm) -0.0050
Est. EPS (GBP) (03/2015) -0.0040
Est. PEG Ratio -
Market Cap (M GBP) 60.73
Shares Outstanding (M) 1,788.83
30 Day Average Volume 9,387,592
Price/Book (mrq) 2.3913
Price/Sale (ttm) 1,993.5483
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 12/02/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RENE

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for RENE

ReNeuron Group PLC is a United Kingdom-based adult stem cell research and development company. The Company is applying its novel stem cell platform technologies in the development of stem cell therapies to serve significant and unmet or poorly-met clinical needs. ReNeuron Group has also leveraged its stem cell technologies into the non-therapeutic areas such as drug discovery.

Michael Elliott HuntChief Executive OfficerJohn SindenChief Scientific Ofcr/Co-Founder
Patrick HugginsSecretary
More Company Profile & Key Executives for RENE

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil